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Insulin in the 
management 
of diabetes mellitus
Insulin is an essential drug used in the treatment of both type 1 and 
type 2 diabetes mellitus. Depsite this, insulin remains one of the 
drugs that is disliked by most patients and health-care professionals. 
It is also a drug that is vey commonly implicated in medication 
errors. Pharmacists are in an ideal position to give the appropriate 
information on insulin to patients with diabetes mellitus every time 
that they come to the pharmacy. More and more patients are being 
switched to insulin analogues, which have greatly improved the 
management of diabetes. 
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Introduction
Diabetes mellitus refers to a group 
of metabolic diseases characterised by 
hyperglycaemia. 
It results from defects in insulin 
secretion, insulin action, or both.1  Insulin is 
secreted from the beta-cells of the pancreas 
and is the hormone needed to enable 
glucose to enter the cells and provide 
energy.2 Insulin is also important in keeping 
blood glucose levels within the acceptable 
limits.2 Thus in patients with diabetes, 
exogenous insulin given as a replacement, 
forms a very important strategy in the 
management of both type 1 and type 2 
diabetes.
Insulin	in	type	1	diabetes
Type 1 diabetes results from a cellular-
mediated autoimmune destruction of the 
beta-cells of the pancreas with consequent 
insulin deficiency.1 Insulin is required for 
survival to prevent ketoacidosis, coma and 
death, thus the term ‘insulin-dependent 
diabetes’ was previously coined to this type 
of diabetes. 
Insulin	in	type	2	diabetes	
Although insulin was originally 
developed for the treatment of type 1 
diabetes, it has gained more importance in 
the management of hyperglycaemia in type 
2 diabetes. Guidelines suggest that insulin 
should not be used as last-line treatment 
when other therapies fail. It should be 
used early on as an additional therapy to 
lifestyle interventions and metformin.4 
Alvarsson et al5 showed that earlier insulin 
use in patients with type 2 diabetes, in 
contrast to sulphonylurea therapy, helps 
preserve beta-cell function and promotes 
better metabolic control with less chance 
of hypoglycaemia. In the second year of 
the study, the effectiveness of the oral 
hypoglycaemic agents that increase beta-
cell function decreased, supporting the 
concept that beta-cells wear out if they 
are continuously overworked. This is not 
the case when insulin is given as treatment 
earlier on since it may temporarily prolong 
endogenous insulin secretion. 
Insulin offers an expected decrease 
in glycosylated heamoglobin (HbA1c) of 
1. – 2.%; which is the largest expected 
decrease in HbA1c when compared to other 
therapies, making it the most effective of 
diabetes medications in lowering blood 
glucose.4 It is also inexpensive when 
compared to other classes of anti-diabetic 
agents.4 There is no dose limit with insulin 
treatment and relatively larger doses are 
required to overcome the insulin resistance 
of type 2 diabetes when compared to doses 
used in type 1.4 
Insulin improves the lipid profile but 
is associated with weight gain of around 2 
to 4 kg.4 This weight is partly due to the 
correction of glycaemia (which presents 
with weight loss) and partly due to the 
reduction of glycosuria.4 Insulin-induced 
hypoglycaemia is less frequent in type 2 
than in type 1 diabetes.4 
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Basal	and	prandial	insulin
It is convenient to think of the insulin 
dose requirement in physiologic terms 
consisting of “basal” and “prandial”. Basal 
insulin refers to background exogenous 
insulin given per unit of time necessary 
to prevent unchecked gluconeogenesis 
and ketogenesis.6 Basal insulin is the 
intermediate- or long- acting component 
of an insulin regimen. Prandial insulin, 
on the other hand, refers to the insulin 
that is necessary to cover meals.6 This 
is represented by short- or rapid-acting 
insulins. In most insulin dose regimens, 
the intermediate- or long- acting insulins 
are given together with short- or rapid-
acting insulins once or twice daily in 
order to mimic the physiological pattern 
of endogenous insulin as secreted by the 
pancreas. 
 
Types	of	insulin
Since the landmark discovery of 
insulin by Fredrick Banting and Charles 
Best in 1922, huge steps have been made 
in research and development of insulin 
preparations.2 Early insulin preparations 
were purified quite crudely from porcine 
or bovine pancreatic tissue. Today, 
insulin is mostly made biosynthetically by 
recombinant DNA technology or genetic 
engineering of human sequence insulin.
Recent advances on human insulin 
resulted in the development of the 
insulin analogues. These analogues are a 
genetically engineered form of insulin in 
which certain amino acids are substituted 
for those found naturally on an insulin 
molecule to improve their pharmacokinetic 
profiles. There are two types of insulin 
analogues, the rapid-acting analogues and 
the long-acting analogues. 
Rapid-acting insulin analogues are 
absorbed faster from the injection site 
when compared to the conventional soluble 
insulin. Thus they readily supply a bolus 
of prandial insulin required to deal with 
postprandial elevations in blood glucose. 
Currently there are three rapid-acting 
analogues namely aspart, glulisine, and 
lispro. The more rapid onset of action 
of these analogues is an advantage over 
regular human soluble insulin. The latter 
has to be injected 0-4 minutes before 
meals to ensure that peak concentrations 
coincide with the elevated post-prandial 
glucose levels. In practice patients might 
tend to inject their insulin at meal times, 
or on the contrary, inject insulin and then 
skip or refuse the meal, with the possibility 
of a hypoglycaemic event. These problems 
were overcome with the development of the 
rapid-acting insulins which can be given 
just before meals. 
Long-acting insulin analogues, that 
is, insulin glargine and insulin detemir 
are released slowly over time and thus 
present a constant level of basal insulin 
or background insulin for the day. Insulin 
glargine is designed to have low solubility 
at neutral pH. It is completely soluble at 
the acidic pH of the injection solution.8 
After injection into the subcutaneous 
tissue, the acidic solution is neutralised 
leading to the formation of micro-
precipitates from which small amounts of 
insulin glargine are continuously released, 
providing a smooth, peakless, predictable 
concentration/time profile with a prolonged 
duration of action. On the other hand, 
insulin detemir has a prolonged duration of 
action since it self-associates strongly at 
the injection site and binds to albumin via 
the fatty acid side-chain.9 Thus detemir is 
released more slowly to peripheral target 
tissues. 
Several studies that compared rapid-
acting insulin analogues with short-acting 
soluble insulin, and long-acting insulin 
analogues with isophane insulin, have 
suggested that insulin analogues reduce 
hypoglycaemia, particularly at night.10  
Several insulin preparations are 
available locally. The conventional ones 
are listed in Table 1, whereas the insulin 
analogues are listed in Table 2. 
Table	1.	Conventional	insulins	available	locally11,12,13
Type	of	insulin Example Colour Onset	of	action	(hours)
Peak	of	action	
(hours)
Duration	of	action	
(hours)
Short-acting Soluble insulin Yellow 0. 1.-. .0-8.0
Intermediate-acting Isophane insulin Light green 1.0-2.0 4.0-12.0 16.0-.0
Intermediate- and short 
acting mixtures Biphasic isophane insulin Brown 0. 2.0-8.0 24.0
Table	2.	Insulin	analogues	available	locally14,15,16,17
Type	of	insulin Examples Onset	of	action	(hours)
Peak	of	action	
(hours)
Duration	of	action	
(hours)
Rapid-acting Insulin aspart Insulin lispro
0.2
0.2-0.0
1.0-.0
0.-2.
.0-.0 
.0-6. 
Long-acting Insulin glargine 1.00 none 24.0
Rapid- and intermediate-acting Biphasic insulin lispro 0.2 1.0-4.0 1.0-24.0
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Practice	points
•	 Insulin should not be used as last-line therapy in type 2 diabetes mellitus but early 
on as an additional therapy to lifestyle interventions and metformin since it preserves 
pancreatic function.
•	 Insulin analogues are produced from genetic engineering of the insulin molecule and 
are associated with reduced hypoglycaemia especially during the night.
•	 Rapid-acting insulin analogues can be given immediately before a meal or shortly 
after if necessary and thus are classified as ‘prandial’ insulins. They are important to 
cover the glucose elevations brought about when meals are consumed.
•	 Long-acting insulin analogues offer a constant ‘basal’ level of insulin and are designed 
in a way so as to offer a peakless concentration of insulin in the body.
•	 Although the syringe and vial are the mostly used insulin delivery system, the insulin 
pen is discreet, less painful when injecting insulin and easier to use especially for 
patients with decreased visual acuity. 
 Similar preparations of insulin 
regardless of manufacturer have the same 
colour on the label. This universal colour 
code was agreed upon by major insulin 
manufacturers following an initiative by 
the International Diabetes Federation 
(IDF).18 Such a colour code helps to reduce 
confusion for patients with diabetes 
especially since patients might recognize 
the type of insulins from the colour on the 
label. Colour coding also proves helpful for 
patients who have to buy insulin abroad 
or from a different source. All parties are 
now actively working together to produce a 
colour code for insulin analogues. 
Onset, peak, and duration of action 
are approximate for each insulin product, 
as there may be variability depending on 
each individual, the injection site, and the 
individual’s exercise program.16
Insulin	delivery	devices
For optimal control of patients with 
diabetes, insulins do not only have to 
match the endogenous insulin as closely as 
possible but they must also be formulated 
and delivered in a way so as to encourage 
patient adherence.
For many years, the vial and syringe 
were the standard means of delivering 
insulin and locally this method is the most 
popular especially among patients with 
Type 2 diabetes. However, the syringe 
carries a stigma and not all patients are 
comfortable to use it. This has implications 
for compliance and glycaemic control. 
The introduction of insulin pens in 
198 has offered several advantages to the 
patient:1
•	 discreet and appears less ‘medical’
•	 injection is less painful since needle is 
shorter
•	 less time consuming 
•	 easier to use especially for patients who 
have impaired eyesight or coordination
•	 more accurate dosing with an audible 
click when the dose is dialed
•	 less wastage of insulin
Better adherence after conversion to 
pen (% vs 6%), reduced likelihood of 
hypoglycaemia episodes, and a decreased 
likelihood of emergency department visits 
have been documented.19 Insulin pens 
however are more expensive than the vial 
and syringe. Insulins cannot be mixed in 
an insulin pen since only one cartridge at 
a time can be put in the pen and thus the 
patient would have to take more injections. 
Pens are available in two different 
forms, with either replaceable cartridges or 
disposable pre-filled cartridges. 
Counselling	patients	on	insulin
Insulin should be stored in a 
refrigerator at 2-80C as suggested by the 
manufacturers.20 However, injecting cold 
insulin can be painful to the patient. To 
overcome this problem, many providers 
suggest storing the vial or cartridge of 
insulin which is in use at room temperature. 
Insulin kept at room temperature has a shelf 
life of one month and patients should be 
advised to write the date of first puncturing 
on the container. The extra supplies of 
insulin which are not in use should however 
be stored in a fridge. Insulin should not be 
stored in extreme heat (e.g. direct sunlight) 
or in extreme cold (e.g. in the freezer). 
Insulin pens should not be stored in the 
fridge. 
Other counselling points that should be 
communicated to patients whilst dispensing 
insulin are found in Panel 1. 
Conclusion
Besides counselling the patient with 
diabetes on storage conditions for their 
insulin, pharmacists are in a unique 
Panel	1.	Insulin	dispensing	practice	points	
1. Insulin should be stored in the fridge; the vial or cartridge in use should be kept 
at room temperature and has a shelf life of 4-6 weeks once punctured.8,9,11-14,1 The 
insulin pen should never be refrigerated. 
2. Soluble and isophane insulins can be mixed together in a syringe; soluble insulin 
is drawn up first and the total volume made up by adding the isophane insulin.12 
Insulin analogues should not be mixed together.8,14
. The 1mL insulin syringe is graduated in 100 units of insulin; the insulin pen gives an 
audible click every time that it is turned and 1 click is equivalent to 1 unit of insulin 
being drawn up from the cartidge to the pen.1
4. Injection sites should be rotated amongst deltoid, thigh and abdomen; injection in 
the abdominal wall enures a faster absorption than other injection sites.12
. Soluble insulin, isophane insulin and the biphasic isophane should all be injected 
half an hour before meals; insulin aspart, insulin lispro and biphasic insulin lispro 
should be given 1 minutes before a meal but if necessary also immediately before 
or soon after a meal; insulin glargine can be given once daily at any time but at the 
same time each day. 8,11,1,14,1,21
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position to provide clinical input into the 
management of this chronic condition. 
Pharmacists may review self-monitoring 
blood glucose readings of patients, help 
in the calculation and titration of insulin 
doses, identify patients with type 2 
diabetes who may benefit from the addition 
of insulin to their regimens, teach the 
injection technique and provide counselling 
on avoiding, recognizing and treating 
hypoglycaemia.
The time when the patient comes for 
refill of insulin at the pharmacy, is an 
opportunity for pharmacists to discuss 
insulin use and diabetes in general and to 
try to motivate the patients. Surprisingly, 
less than 40% of patients with diabetes 
know their HbA1c levels and only 2% 
accurately reported that value.22 It is 
important for patients to know what their 
HbA1c level is so that they know whether 
their diabetes is improving or worsening. 
Patients should also be knowledgeable 
about the relationship between poor 
glycaemic control and health risks.
Insulin is in general disliked by 
the majority of patients. Barriers to 
its use include a belief that insulin 
causes complications or death, fear of 
hypoglycaemia and weight gain, perception 
of insulin treatment as complicated and 
difficult, and a feeling of failure from their 
part if insulin is initiated.1
Thus the advantages of adding insulin 
earlier on in their treatment should be 
translated to the patient and goals of 
treatment should be made clear. Patients 
should be made aware of the advantages 
of the insulin analogues in mimicking the 
endogenous insulin system and also in their 
association of less hypoglycaemic events 
and less weight gain reports. Moreover, 
patients with diabetes should be reassured 
that the initiation of insulin is not a sign of 
treatment or condition failure. It should be 
explained to them that diabetes is a chronic 
condition and that insulin helps to preserve 
pancreas function.1
Pharmacists are now more than ever in 
a good position to make a difference in the 
life of a patient with diabetes.
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